Treatment of Breast Fibroadenoma Targeted Tissue With HIFU

NCT ID: NCT03044054

Last Updated: 2024-10-15

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-01-31
• Study Completion Date: 2024-11-30

Brief Summary

This study evaluates the efficacy and the safety of the HIFU for the treatment of breast fibroadenoma.

Detailed Description

Echopulse is specially designed, manufactured and CE marked for treating breast fibroadenoma. HIFU is a completely alternative to surgery which utilizes high-energy ultrasound to deliver a large amount of sound energy to a focal point to rapidly induce tissue heating to 85-90°C.This initiates tissue coagulation followed by tissue necrosis ablating the targeted area.

Conditions

Breast Fibroadenoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ECHOPULSE

ECHOPULSE HIFU

Group Type: EXPERIMENTAL

ECHOPULSE

Intervention Type: DEVICE

HIFU Under ultrasound guidance

Interventions

ECHOPULSE

HIFU Under ultrasound guidance

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Female patients 18 years or older diagnosed with breast fibroadenoma and presenting at least one fibroadenoma.

2. Diagnosis of fibroadenoma must be based on:

1. Clinical examination

2. Ultrasound image alone for patients under 35 years old. For women older than 35 years, a mammogram will be performed in addition to ultrasound. The BI-RADS score of this mammogram must be 2 or 3. BI-RADS score of 4 is eligible if biopsy indicates fibroadenoma with concordance.

3. Histologic confirmation by core needle biopsy.

3. Patient is a candidate for the surgery.

4. The fibroadenoma treatment volume must be at least 5 mm and no more than 26 mm from the skin. This criterion should be evaluated immediately prior treatment, once the breast is immobilized and potentially compressed.

5. The rib cage should not be in the prefocal ultrasound path or behind the target fibroadenoma (minimum distance from the posterior wall of the fibroadenoma must be at least 10 mm). This criterion shall be evaluated immediately prior to treatment, once breast is immobilized and potentially compressed.

6. The fibroadenoma is 1 cm or greater at its largest dimension and no less than 7.5 mm in the anterior-posterior dimension (measured by ultrasound). Focal point for HIFU treatment must also be at least 3 mm from any border of the fibroadenoma.

7. Patient's fibroadenoma size is greater or equal to 0.2 cc and less than 10 cc in volume (measured by ultrasound on the day of the procedure).

8. Fibroadenoma is palpable.

9. Pain ≥ 30mm/100mm measured on VAS as a maximum level during the last 30 days

10. Anxiety ≥ 30mm/100mm measured on VAS as a maximum level during the last 30 days

11. Patient has signed a written informed consent.

Exclusion Criteria

1. Patient is pregnant or nursing.

2. Presence of calcified fibroadenoma. Calcification will be determined with mammography. In women > 35 years old, the diagnostic mammogram should be evaluated for calcification. In women ≤ 35 years old, a single view mammogram of the affected breast is sufficient for evaluation of calcification. Women ≤ 35 years old will be excluded based on the findings of calcification on a single view mammogram.

3. Patient with history of breast cancer or history of laser or radiation therapy to the target breast.

4. Patient with breast implants in the target breast.

5. Patient with a breast cyst within the fibroadenoma to be treated.

6. Patient's fibroadenoma not clearly visible on the ultrasound images (in B mode) at the inclusion visit.

7. Patient participating in another clinical trial involving an investigational drug, device or biologic.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Theraclion

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michel NUTA, MD

Role: STUDY_DIRECTOR

Theraclion

Locations

Bellevue Hospital Center

New York, New York, United States

Site Status: COMPLETED

New York Columbia University Medical Center

New York, New York, United States

Site Status: COMPLETED

Montefiore-Einstein Center for Cancer Care

New York, New York, United States

Site Status: COMPLETED

University of Virginia Health system

Charlottesville, Virginia, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Michel NUTA, MD

Role: CONTACT

michel.nuta@theraclion.com

633404004

Facility Contacts

Katie Rea

Role: primary

Other Identifiers

HIFU/FA/003

Identifier Type: -

Identifier Source: org_study_id